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Tuberculosis remains a major cause of mortality and morbidity on a global scale. Effective
anti-tuberculous chemotherapy has improved outcomes for individuals suffering from
tuberculosis, although the disease often results in significant and permanent damage to
organs. The use of adjunctive corticosteroid treatment has been studied with a view to
demonstrating a reduction in inflammatory events that may improve outcomes for both
mortality and morbidity. Cochrane reviews have summarized the evidence for adjunctive
corticosteroids in the treatment of tuberculous pericarditis, meningitis and pleural
effusion. These reviews have shown improved mortality for pericarditis and meningitis, but
inconclusive effects for pericardial constriction and ongoing neurological disability. Rapid
improvements in clinical parameters for pleural effusion were not supported by any lasting
improved outcomes for these patients.
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Tuberculosis remains a major cause of mortality and
morbidity on a global basis. Despite the use of effective
anti-tuberculous treatment regimens, the disease still poses
serious risks to patients. In addition to the untoward
consequences of overwhelming infection, the inflammatory
reaction to Mycobacterium tuberculosis can result in
significant tissue damage. Healing, particularly by fibrous
scarring, can render organs severely damaged and dysfunc-
tional. Therefore, the long-term disabling effects of treated
tuberculosis remain an important challenge. Vital organ
systems, such as the central nervous system (CNS), heart,
genitourinary tract and the lungs are especially vulnerable.
Corticosteroids have been prescribed to treat a wide
range of disorders for many years, and the use of these drugs
as part of the management of tuberculosis is documented. In
particular, steroids are essential in the case of adrenocor-
tical failure caused by the disease. Outwith this specific
indication, suppression of unwanted inflammatory events
arising in response to infection with M. tuberculosis seems
logical. However, steroids have immunosuppressive effects,
and concerns remain that their routine use might actually
worsen outcomes in some cases of tuberculosis because of
failure of immune response against the organism. Notwith-
standing this anxiety, the possibility that anti-tuberculous
agents may show reduced efficacy because of reduced
penetration of the drugs into infected tissues (because of
steroid anti-inflammatory effects) has also been studied.
These issues have been addressed by three Cochrane
systematic reviews. They have drawn together the published
evidence for the use of steroids in the treatment of
pericardial,1 pleural2 and meningeal tuberculosis.3
In this evidence-based review, issues pertinent to the
pathology and outcome of tuberculosis in these three organ
systems are addressed, with reference to the use of
adjunctive steroids. Data that have informed the conclu-
sions of the Cochrane reviews, and the position of current
guidelines published by the National Collaborating Centre
for Chronic Conditions,4 will also be discussed.
Tuberculous pericarditis
Pericarditis is a feature of about 1% of cases of tuberculosis
at autopsy, and it is clinically apparent in up to 2% of
pulmonary tuberculosis.5 Worldwide, tuberculosis remains
the most common cause of pericarditis,6 although in
developed countries it is only relevant to the causation of
pericarditis in 4% of cases.7 However, the emergence of co-
morbid HIV as a predisposing factor for tuberculosis has
resulted in an increase in the incidence of tuberculous
pericarditis.8
Tuberculous pericarditis is characterized by three main
clinical stages: effusive, effusive–constrictive and constric-
tive. Constrictive tuberculous pericarditis is thought to be alate complication of effusive pericarditis and arises in
30–60% of cases.9 The mortality of tuberculous pericarditis
is variously reported at 14%,10 17%11 and 40%,12 and largely
determined by late constriction. Although the outcome for
tuberculous pericarditis has improved after the introduction
of effective anti-tuberculous drug regimens, the issue of
preventing progression to constriction remains unclear.13
The most appropriate treatment for tuberculous pericar-
ditis has evolved from research evaluating anti-microbial
agents and interventions such as pericardiocentesis and
pericardectomy. National guidelines recommend standard
chemotherapy with rifampicin, isoniazid, pyrazinamide and
ethambutol for 2 months followed by rifampicin and
isoniazid for 4 months.4 The additional use of oral steroids
has also been the subject of clinical trials, and the collective
evidence has been synthesized in two systematic reviews
with some limited meta-analyses.1,14
One of the earliest studies evaluated effusive pericarditis
treated with isoniazid, streptomycin and para-aminosalyci-
lic acid (PAS).15 Twenty-eight participants were allocated to
steroids (alternate days) or no steroids for an undisclosed
period of time. The end point was the development of
constriction requiring pericardectomy. Despite shortfalls in
study design, steroid treatment was not found to be
effective.
A further study by Rooney et al.16 reported a retro-
spective series among 28 patients with effusive pericarditis
treated with isoniazid, streptomycin and PAS. Eighteen
patients also received prednisolone 60mg daily, tapered
over 6–8 weeks. The group treated with steroids showed
more rapid resolution of their pericardial effusions. None of
the people in the steroid group died, although four patients
died in the placebo group. In both limbs of the study, four
individuals required pericardectomy, although the remain-
der of the patients treated with prednisolone improved
(14 out of 18). The data were not subjected to statistical
analyses.16
Strang et al.10,17 published two randomized-controlled
trials evaluating the use of steroids in constrictive and
effusive tuberculous pericarditis, respectively, among pa-
tients from Transkei. The first study reported the outcome
for a group of 143 patients with constrictive pericarditis
treated with a standard regimen of anti-tuberculous treat-
ment over 6 months (rifampicin, isoniazid, pyrazinamide
and streptomycin) and thereafter followed up for a 2-year
period.17 One hundred and fourteen patients were asses-
sable for the full 24 months. The study showed significantly
improved outcomes for the patients treated with steroids
over the first 10 weeks in clinical parameters (e.g. heart
rate, jugular venous pressure [JVP] and physical activity)
and apparently reduced mortality during follow-up (4%
prednisolone vs. 11% placebo). Fewer patients treated with
steroids required pericardectomy (21% prednisolone vs. 30%
placebo). However, both prednisolone and placebo groups
showed good outcomes at the end of the 2-year trial, with
94% and 85% of patients, respectively, fulfilling specified
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derived over the first 10 weeks of this trial, limited
statistical analysis was carried out to allow definite
conclusions to be drawn from these data (in particular the
mortality and pericardectomy findings).
The second trial from from Strang et al. published results
for 240 patients suffering from effusive pericarditis treated
with the same anti-tuberculous regimen over 6 months and
also followed for 2 years.10 At study entry, patients were
offered open pericardial drainage (and biopsy). Thereafter,
patients were randomly prescribed prednisolone (initial
adult dose 60mg daily) or placebo over 11 weeks. Those
individuals unwilling to undergo open drainage of the
pericardial effusion at entry were also allocated to either
prednisolone (same dose and duration) or placebo with
pericardiocentesis as required. 150 patients were the
subject of comparison between prednisolone and placebo
treatments. The results showed a significant reduction in
mortality (3% prednisolone vs. 14% placebo) and repeat
pericardiocentesis. The need for open drainage of effusions
(in those not so treated at study entry) and pericardectomy
was also reduced, although these differences in favour of
steroid treatment did not reach significance. Twelve
patients died (three prednisolone vs. nine placebo), but
the remainder of the patients showed favourable status at
24 months, irrespective of their initial prednisolone or
placebo treatment.
The patients reported by Strang et al.10,17 were followed
up for a further 10 years, and the results also published.18 A
96% follow-up rate was achieved. Patients who had
participated in the first trial (i.e. pericardial constriction17)
showed improved adverse outcomes inclusive of death,
pericardectomy, repeat pericardiocentesis or open drainage
of pericardial effusion. Specifically, 27% of these patients
previously treated with prednisolone compared with 38% of
patients in the placebo group suffered adverse outcomes,
although these differences were not significant. There were
2 (3%) deaths due to pericarditis amongst the prednisolone
patients and 8 (11%) for the placebo group (p ¼ 0.06). For
those patients with effusion,10 adverse outcomes were
significantly less for patients treated with prednisolone that
did not undergo drainage of pericardial effusion at the
outset (19% prednisolone vs. 40% placebo; P ¼ 0.003).
Furthermore, prednisolone reduced the need for repeat
pericardiocentesis (10% vs. 23%, P ¼ 0.025). However,
among those patients who underwent pericardial drainage,
but did not receive prednisolone, only 11% experienced
adverse outcomes. Analysis of all of the mortality data from
both trials conferred significant advantages of prednisolone
treatment for risk of death from pericarditis.18
Experience is limited for the use of corticosteroids in the
treatment of HIV-positive individuals suffering from peri-
cardial tuberculosis. Key trial data were reported by Hakim
et al.19 following a double-blind, randomized, placebo-
controlled trial. Fifty-eight HIV-positive individuals suffering
from clinically and echo-diagnosed pericardial tuberculosis
were randomized to receive prednisolone (initially 60mg
daily tapering over 6 weeks) or placebo alongside a standard
6-month anti-tuberculous chemotherapy regimen. The cases
were followed up for 18 months. Steroid treatment reduced
mortality (prednisolone five deaths vs. placebo 10 deaths;
P ¼ 0.004). Resolution of clinical parameters was quicker inthose patients treated with steroids: JVP (P ¼ 0.017),
hepatomegaly (P ¼ 0.007), ascites (P ¼ 0.015) and physical
activity (P ¼ 0.02). However, no differences were found
between groups for radiological or echocardiographic
resolution of pericardial effusion.19
The Cochrane review evaluating the management of
tuberculous pericarditis considered trials showing data for
steroid use and surgical intervention (pericardectomy or
pericardiocentesis1). Four trials were included, with a total
of 469 participants.10,16,17,19 The review acknowledged
differences between the studies in effusive17 and constric-
tive10 types of pericarditis as well as HIV status.19 Accord-
ingly, limited meta-analysis was possible. The review
showed a reduction in death from pericarditis in patients
treated with steroids (RR 0.43, 95% CI 0.18–0.99) and a
trend in favour of steroids for all-cause mortality (RR 0.65,
95% CI 0.36–1.16). For death or persisting disease at 2 years,
there were also effects in favour of steroid intervention
(RR 0.69, 95% CI 0.48–0.98), although heterogeneity was
found between the trials contributing to this summary
outcome, and therefore the authors preferred to show the
trial effects separately.10,17 The need for repeat pericardio-
centesis was reduced by steroids (0.45, 95% CI 0.2–0.1.05),
although the summary statistic assessing the need of
pericardectomy did not differ between treatment groups
(0.85, 95% CI 0.51–1.42). The only data in the review for HIV
patients was that derived from the study by Hakim et al.19
The authors concluded that their review had shown
potential benefits for the use of steroids in the treatment
of pericarditis but, given that the published trials were
small, they recommend large placebo-controlled trials to
confirm their findings.
Current guidelines published by the National Collaborat-
ing Centre for Chronic Conditions recommend the use of
corticosteroids in the treatment of pericardial tuberculosis.
This recommendation is also extended to the treatment of
children.4
In summary, the available trial data show effects
supporting the use of steroids in the treatment of
pericarditis in both HIV-negative and positive patients.
However, the evidence is limited as the number (and size)
of trials informing this question are few. Furthermore, not
all the reported end points were unequivocally in favour of
steroids. Therefore, adjunctive corticosteroids should be
considered after careful case-specific assessment, in parti-
cular in the instance of HIV-positive patients.Pleural tuberculosis
Pleural effusions occur in up to 30% of cases of tuberculosis
and typically in young adults as an immunological phenom-
enon at the time of primary infection. However, the
epidemiology and demography of tuberculous pleurisy
has changed during recent years owing to the impact
of co-morbid HIV infection and the increasing numbers of
cases arising at the time of post-primary tuberculosis
(reactivation).20 Although the incidence of pleural effusion
in HIV-infected cases with tuberculosis seems to be similar
to that seen in non-HIV related cases, significant issues are
related to the outcome of tuberculosis in HIV-infected
individuals, which make this distinction important.21
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foci and the release of mycobacterial antigens into the
pleural space, which elicit an immunological response
(delayed hypersensitivity). The effusion is characteristically
exudative and lymphocytic. Diagnosis is dependent on
pleural biopsy and from samples of pleural fluid for culture.
Molecular techniques and measurements of pleural fluid
adenosine deaminase (ADA) also assist in diagnosis. How-
ever, given the indifferent yields arising from pleural
methods and their lack of sensitivity, the diagnosis is often
based on clinical grounds or other analyses such as sputum or
bronchial washings and skin testing.22
Tuberculous effusions may resolve and heal without any
long-term sequelae. However, in some instances, the
‘healing’ of effusions arises with a legacy of pleural fibrosis,
possibly due to disordered fibrin turnover, whereby an
imbalance between fibrin deposition and fibrinolysis occurs.
Pleural fibrosis can result in clinically relevant pleural
thickening and impairment of lung function. Estimates for
this outcome vary, although some authors have cited pleural
thickening in as many as 50% of cases.23 Therefore, the
intent of treatment is to foreshorten the acute phase of the
disease and to restore the integrity of the pleura preventing
lasting fibrosis and thickening.
A number of uncontrolled studies, completed before the
use of modern anti-tuberculous chemotherapy, have shown
the benefits of steroids used as adjuncts to drugs such as
isoniazid, PAS and streptomycin.24–26
Thereafter Grewel et al.27 examined 102 cases of pleural
tuberculosis and showed the benefits of adding oral steroids
to anti-tuberculous chemotherapy compared with intra-
pleural administration of steroids and multiple pleurocent-
eses. Nonetheless, intrapleural steroids showed improved
outcomes compared with no steroid treatment at all. End
points included resolution of fever, improvements in X-ray,
reduction in ESR and prevention of subsequent pleural
thickening. Grewel et al.27 were only able to report proven
tuberculosis (by culture) in 10 of their 102 cases. None-
theless, this result typified the results of other earlier
studies.
Three other randomized, placebo-controlled trials have
re-examined the use of steroids in the treatment of pleural
tuberculosis, and these trials constitute the body of current
evidence available in the modern antibiotic era.28–30 Lee
et al.28 reported the outcome for 40 patients randomized to
receive prednisolone 0.75mg/kg/day or placebo in parallel
with a combination of rifampicin, isoniazid or ethambutol
for 2 months followed by rifampicin/isoniazid for a further
6–9 months. The steroids were given for 2–3 months. All
patients underwent an initial pleural biopsy and diagnostic
pleurocentesis (50ml). The diagnosis was confirmed by
culture or characteristic histology (chronic granulomatous
inflammation). Significant differences were observed be-
tween the groups in resolution of symptoms such as fever,
chest pain, dyspnoea (2.4 days steroids vs. 9.2 days placebo)
and clearing of the radiographic features of effusion (54.5
days steroids vs. 123.2 days placebo). Although fewer
patients treated with steroids developed pleural adhesions
or thickening, the difference for this outcome did not reach
statistical significance.28
Galarza et al.29 studied 117 patients with pleural
effusions of probable or proven tuberculous cause. Thediagnosis of tuberculosis was confirmed in 63% of cases
(culture or histology). All patients received rifampicin/
isoniazid for 6 months. Individuals were randomly assigned
to receive prednisone 1mg/kg/day or placebo. The steroids
were given in full dose for 15 days and then tapered to zero
after 1 month of treatment. Pleurocentesis was carried out,
removing fluid until one-third of the hemithorax was
observed to be occupied on a standard chest radiograph.
Patients were followed up for 1 year. The investigators
reported a similar duration for fever, although statistically
significant differences were found for the initial reabsorp-
tion of the effusion over 1 month in favour of steroid
treatment (although this effect was not sustained). One
patient in the steroid group developed pleural thickening
compared with five patients in the placebo group. This
difference, however, was not statistically significant. In
parallel with this finding, no differences for measures of
lung function were observed between the groups. The study
concluded that there was no evidence to support the use of
prednisone in tuberculous pleurisy. The authors commented
on the satisfactory results seen in placebo group, and
suggested that higher dose steroid treatment was unlikely to
confer any further advantage.
The outcomes for 70 patients with proven tuberculous
pleurisy were reported by Wyser et al.30 Individuals were
randomized to prednisone 0.75mg/kg/day or placebo
(for up to 4 weeks) alongside rifampicin, isoniazid and
pyrazinamide (over 6 months). All patients underwent
thoracoscopy at the outset of the trial in order to establish
the diagnosis as well as to achieve complete drainage of the
effusion. Patients were followed up for 24 weeks with serial
clinical reviews, full lung function and high-resolution
computed-tomography imaging. Statistically significant im-
provements in symptoms (appetite, night sweats, tiredness,
cough and chest pain) occurred earlier in patients taking
steroids (8 weeks) than in those taking placebo (12 weeks).
However, ultimately, no differences were found in outcome
for any of the chosen end points. The proportion of patients
with pleural thickening between the groups showed no
difference (53.1% steroids vs. 60% placebo, non-significant).
Furthermore, no demonstrable differences were found for
measures of lung function between the study groups. The
authors concluded that the thoracoscopic drainage of the
pleural fluid at the beginning of the trial was the key
determinant of recovery, and that the data did not support
the use of steroids in the treatment of the condition.
The collective experience for these trials has been
published by Matchaba and Volmink2 in a Cochrane
systematic review reporting summary effects for the use
of steroids in the treatment of tuberculous pleurisy. This
review acknowledged all the various trials, but was only able
to include three studies that fulfilled a randomized and
placebo-controlled design.28–30 Therefore, the review cites
experiences across 236 patients. Accordingly, there were
few outcome measures allowing meta-analyses, specifically
residual fluid at the end of treatment and residual pleural
thickening. In the case of residual fluid, no effect of steroid
treatment was found (RR 0.28, 95% CI 0.06–1.34). This result
was only informed by two of the studies, as the patients
in the third trial underwent thoracoscopy and drainage
at the beginning of treatment.29 Similarly, for residual
pleural thickening, the meta-analysis showed no difference
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the three trials (RR 0.76, 95% CI 0.48–1.21). No significant
adverse effects of steroid treatment were found. The
authors concluded that there was insufficient evidence to
determine whether steroids are effective in the treatment
of tuberculous pleural effusions.
The Cochrane review did not include data from HIV-
positive patients suffering with tuberculous pleurisy. Lat-
terly, a trial from Uganda31 has reported on the outcome for
a group of such patients (over an 18-month follow-up
period). The authors considered outcome for pleurisy as well
as issues pertaining to HIV-related morbidity and mortality.
Specifically, the trial examined the likelihood of an unto-
ward interaction between co-morbid tuberculosis and HIV
disease, possibly arising from immune activation and
promoted HIV replication. Prednisolone treatment over the
initial 8 weeks of a 6-month anti-tuberculous regimen
showed significant effects for more rapid improvements in
symptoms (cough and anorexia) but no benefits for mortality
among a group of 198 individuals with culture or histologi-
cally proven pleural tuberculosis. Radiological resolution
of the effusion was quicker and more complete among
patients treated with prednisolone, although the paper does
not cite outcome for enduring pleural thickening. Although
no effects were found for prednisolone on the incidence of
HIV-related opportunistic infections, six individuals in the
steroid group did develop Kaposi’s sarcoma (none in the
placebo arm). Accordingly, the trial authors did not
recommend the use of prednisolone in the treatment
of tuberculous pleurisy in HIV-positive patients because
of the lack of lasting benefit/survival and also because of
concerns about the occurrence of Kaposi’s sarcoma.
On balance, the evidence does not support the use of
steroids in the treatment of pleural tuberculosis. Collec-
tively, the trials confirm an initial benefit in rapid resolution
of effusion and symptom control. However, no lasting
advantage was found, in particular none for the develop-
ment of fibrosis and pleural thickening.
Current national guidelines do not comment on the use of
steroids under their recommendations for treatment.4
Previous guidelines published by the British Thoracic Society
cite the aforementioned trials and suggest that steroids may
have a role in the suppression of hypersensitivity reactions
but do not state a definite approach.32Tuberculous meningitis
Most tuberculous infections involving the CNS are caused by
M. tuberculosis, and meningitis is the most common form.
Meningitis is the most serious extra-pulmonary manifesta-
tion of tuberculosis, resulting in death or severe neurologi-
cal deficits in about half of cases.33
CNS infection probably occurs as a result of haematogen-
ous spread due to infection elsewhere in the body, such as
might arise at the time of primary infection. Initially, small
lesions develop (Rich’s foci), and these may remain
quiescent for many years. Later, rupture of these foci can
result in infection and cause any of the types of CNS
tuberculosis, in particular meningitis. In keeping with other
post-primary tuberculous infections, the stimulus for re-
activation is often not completely understood, althoughimmunosuppression from various causes is likely to be a key
factor.34
The meningitis is typically most pronounced over the
basal meninges where gelatinous exudates are formed. This
meningeal pathology results in direct injury to the under-
lying brain tissue. Because of the proximity of the Circle of
Willis, a vasculitic inflammation of key vessels also arises.
Consequently, further cerebral injury secondary to infarc-
tion (often complicated by haemorrhagic transformation) is
manifest, especially in the distribution of the medial striate
and thalamoperforating arteries. Hydrocephalus as a result
of obstruction to cerebrospinal fluid (CSF) is also frequently
observed. Collectively, these pathological processes under-
pin the usual picture of multiple cranial nerve palsies that
characterize tuberculous meningitis.35
The presentation is often preceded by a history of malaise
and fatigue, with low-grade fever over a few weeks.
Latterly, a progressive headache develops culminating in
features of meningism. As stated, cranial nerve palsies may
evolve. In advanced disease, apathy, seizures, coma and
decerebrate rigidity preface a terminal outcome.34
Previously, the disease has been classified into three
typical stages.36 Stage one meningitis describes mild cases
without altered consciousness or focal neurological deficit,
Stage two—altered consciousness (without coma) showing
moderate neurological deficits and Stage three—coma and
neurological deficits inclusive of cranial nerve palsies and
bilateral neurological signs.
The diagnosis is based on clinical features, imaging and
CSF findings. CSF lymphocytosis and increase in protein
levels with diminished glucose concentrations are usual,
although polymorphonuclear leucocytosis may be apparent
during the earlier phases of the illness. Definitive diagnosis
is provided by the finding of acid-fast bacilli on microscopy,
molecular methods or subsequently from the culture.34
Experience indicates that outcome (death or severe
neurological deficits) is not solely linked to timely and
effective use of anti-tuberculous drug treatment. This is
borne out by the experience from early treatment trials.
Whilst showing significant mortality benefits with the
introduction of antibiotics (streptomycin/PAS/isoniazid)36,37,
more sophisticated regimes using the full array of newer
agents did not lead to further dramatic improvements in
survival and the mortality for stage three disease remained
at approximately 50%.38 Furthermore, reports on the use of
modern anti-tuberculous regimens have shown little effect
on the incidence of residual neurological disabilities among
survivors.38,39
Corticosteroids used to reverse inflammatory elements in
tuberculous meningitis have been the subject of a number of
trials. However, it has been difficult to draw any definitive
conclusions from earlier studies because of a lack of
participants and other methodological factors.
The first trials in the 1950s suggested benefits for the use
of cortisone.40,41 Later studies found similar results.42,43 In
contrast, some investigators have raised concerns that
steroid treatment may worsen outcome, given the possibi-
lity that reduced meningeal inflammation may inhibit the
concentrations of anti-tuberculous drugs within the CSF.44 In
fact, this is now not thought to be the case.45
Girgis et al.46 reported the outcomes for 160 individuals
of culture-proven tuberculous meningitis in a non-controlled
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(dexamethasone administered systemically) showed signifi-
cantly improved survival, in particular among stage two and
three cases (mortality; dexamethasone 43%, control 59%).46
A further report from the same group of investigators
including experience from 857 cases of confirmed tubercu-
lous meningitis over a 20-year period showed that the use of
dexamethasone resulted in significantly reduced ocular
complications and other neurological sequelae. Overall, this
latter trial confirmed that mortality was particularly
dependent on stage of disease and duration of illness at
presentation.47
Schoeman et al.48 reported the effects of prednisolone
among 141 children with tuberculous meningitis (stages two
and three). The diagnosis was based on a number of key
factors, inclusive of CSF and typical CTappearances, but not
necessarily on culture proof. Prednisolone was given to 70
individuals for 1 month. Steroids resulted in a significant
reduction in mortality and enhanced resolution in basal
exudates and tuberculomas (where present) but no sig-
nificant effects on raised intra-cranial pressure or the
incidence of basal ganglia infarction. No differences were
found in motor deficit, blindness or deafness. The children
treated with steroids had better IQ at 6 months; however,
this latter benefit did not seem to be enduring given the
findings of the same group who reported long-term out-
comes for 23 of the children (after about 6.5 years).49
Specifically, the authors reported no difference for intellec-
tual performance between children treated with steroids
and control individuals.
Kumarvelu et al.50 reported the results for 47 cases of
tuberculous meningitis (ages 12–78 years). Patients were
treated with dexamethasone for the initial 4 weeks of a
1-year anti-tuberculous regimen. The authors reported earlier
improvements for patients treated with steroids, although no
significant effects for dexamethasone were shown for death or
disabling residual deficits.50
Thwaites et al.51 recently published a randomized,
placebo-controlled trial evaluating 545 patients over the
age of 14 years with tuberculous meningitis in Vietnam. This
trial showed no significant difference for the combined
outcome of death or severe neurological disability between
cases treated with dexamethasone or placebo. In addition,
the incidence of lesser degrees of neurological disability was
not altered by the use of steroid treatment. However, the
use of steroids did result in significantly improved outcome
when the analysis was limited to fatality alone (RR 0.60, 95%
CI 0.52–0.92). Secondary outcomes inclusive of length of
hospital stay, coma resolution and relapse rates were not
different between groups, although patients treated with
steroids had shorter duration of fever. The study included
analyses for 98 HIV-infected patients. The case fatality rate
across both treatment groups was higher among HIV-
infected individuals. A trend was also observed for improved
outcome for HIV patients receiving steroids (RR 0.78,
0.59–1.04; P ¼ 0.08). Significantly more adverse events,
such as hepatitis, were reported in the placebo group than
the patients treated with dexamethasone. Therefore, anti-
tuberculous treatment was altered because of adverse
events on 62 occasions in the dexamethasone group and on
81 occasions in the placebo group. Furthermore, treatment
changes of this type were independently associated withdeath. No adverse events directly related to steroid
treatment were reported. In conclusion, the authors stated
that the early use of dexamethasone reduced mortality from
tuberculous meningitis (regardless of stage) but did not alter
the occurrence of severe disability among survivors.51
The Cochrane review for randomized-controlled trials
evaluating the use of steroids in tuberculous meningitis was
published in 2000.3 This review does not include the data
derived from the study by Thwaites et al.51 The review
included trials examining children and adults, all stages of
the disease and various anti-tuberculous regimes.46,48,50,52–54
The review was not able to address the issue of HIV, as
insufficient data were available from the included studies to
undertake analyses. Therefore, all but one54 of the studies
did not investigate the HIV status of patients, and conclu-
sions need to be interpreted with this unknown factor in
mind. The authors also highlighted a lack of allocation
concealment across the included studies, small study sizes
and possible publication bias. Despite these limitations, 595
patients from six trials were included. Meta-analyses
showed significantly reduced overall mortality (RR 0.79,
95% CI 0.65–0.97), reduced death and severe residual
disability (RR 0.58, 95% CI 0.38–0.88), and reduced death
in children (RR 0.77, 95% CI 0.62–0.96). However, mortality
analysis limited to adults alone did not show any effects (RR
0.96, 95% CI 0.5–1.84).
Current national guidelines4 recommend the use of
additional steroids for the treatment of tuberculous
meningitis in the light of the available evidence, in
particular the data arising from the Vietnamese trial.51 This
recommendation was also informed by knowledge that this
disease has a high mortality and potential for severe
neurological deficits in survivors. It is recommended that
the effects of steroids should be assessed within a month of
starting treatment, with a view to tapering treatment as
soon as deemed safe.Conclusion
All of the trial data informing the evidence base should be
compared after careful consideration of the various steroid
doses prescribed, given the crucial drug interaction between
rifampicin and corticosteroids. Specifically, the effective
dose of prednisolone is about half the ‘taken’ dosage due to
this interaction.
The Cochrane reviews show benefits for the use of
steroids in pericardial and meningeal tuberculosis. However,
the authors of these reviews have not concluded definitive
results in favour of adjuvant treatment. Mortality benefits
have been shown by randomized placebo-controlled trials.
Survival benefits in pericarditis do not seem to translate into
unequivocally improved outcomes for pericardial constric-
tion (as is shown by the need for pericardectomy).
Similarly, in meningitis, the outcome of severe neurolo-
gical disability is not clear. The Cochrane review showed
improved outcome for individuals treated with steroids,
although the latest trial (not included in the review) failed
to show this benefit.
The explanation for the conflict between mortality
and outcome for serious disabilities among survivors with
pericarditis or meningitis is not forthcoming from the
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processes and the clinical diversity that exists among
presenting cases may account for this difference. The
Cochrane reviewers recommend further research trials.
Although adjuvant steroids seem to confer initial benefits
in the treatment of pleural tuberculosis, the clinical trial
data do not support any lasting improved outcomes. The
Cochrane review concluded insufficient evidence in favour
of steroid treatment.
Possible adverse effects from steroids were addressed in
the trials included in the reviews, although a lack of data
precluded any detailed meta-analysis. None of the trials
reported dissemination of tuberculosis owing to possible
immunosuppressive effects of adjuvant steroids. Indeed, the
results reported by Thwaites et al.51 showed that patients
treated with steroids had less hepatitis when taking anti-
tuberculous drugs, and this resulted in reduced interruption
and changes in the antibiotic regimen.
With the possible exception of an excess of cases of
Kaposi sarcoma, the limited evidence for adverse outcomes
among HIV positive patients does not show any obvious
untoward effect for steroid treatment in the management of
tuberculous pericarditis, pleural effusion or meningitis.
Nonetheless, the issue of Kaposi sarcoma does warrant
caution.
National Guidelines, drawing on systematic reviews
and key studies, have supported the use of adjuvant
steroid treatment for meningeal and pericardial tubercu-
losis. However, larger and appropriately powered rando-
mized-controlled trials are required to confirm these
recommendations.Practice points
 Available evidence indicates that adjunctive ster-
oids should be considered in the treatment of
pericardial tuberculosis.
 There does not seem to be any lasting benefit from
the use of adjunctive steroids in the treatment of
tuberculous pleural effusions.
 Available evidence recommends the use of adjunc-
tive steroids in tuberculous meningitis. Steroids
improve survival and may reduce the incidence of
lasting neurological disabilities, although the trial
data for this outcome are conflicting.Research agenda
 For both tuberculous pericarditis and meningitis,
appropriately powered randomized-controlled trials
are needed. These should address the apparent
conflict that exists in the current evidence between
improved mortality outcomes but equivocal benefits
in relation to lasting disability (meningitis) and
pericardial constriction.
 The Cochrane reviews undertaken for tuberculous
pericarditis, meningitis and pleural effusion have
not been able to conclude on the issue of possible
adverse events relating to steroid treatment.Although no untoward outcomes have been identi-
fied from the current evidence, further trial data
are required to evaluate this issue further.
 The issue of adjunctive steroid treatment in HIV
patients suffering from tuberculous pericarditis,
meningitis and pleural effusion requires further
study.Conflict of interest statement
The author declares no conflict of interest in respect to this
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